Home » Ganetespib Synergizes with Taxanes in Multiple NSCLC Models, Synta Says
Ganetespib Synergizes with Taxanes in Multiple NSCLC Models, Synta Says
Ganetespib, a non-ansamycin inhibitor of Hsp90, enhances the activity of the microtubule targeting docetaxel, paclitaxel, and vincristine in multiple non-small cell lung cancer (NSCLC) xenograft models, according to an article published in the journal Investigational New Drugs. Ganetespib currently is being studied in combination with docetaxel in a Phase IIb/III clinical trial (GALAXY) in NSCLC.
MarketWatch
MarketWatch
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May